Two studies suggest that low levels of antibodies, when present continuously, effectively limit or prevent HIV infection (pages 951–954 and 901–906). The findings provide hope for the development of a vaccine.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Katie Vicari
References
Igarashi, T. et al. Nat. Med. 5, 211–216 (1999).
Haigwood, N.L. et al. J. Virol. 78, 5983–5995 (2004).
Nishimura, Y. et al. J. Virol. 76, 2123–2130 (2002).
Hessell, A.J. et al. Nat. Med. 15, 951–954 (2009).
Johnson, P.R. et al. Nat. Med. 15, 901–906 (2009).
Hessell, A.J. et al. PLoS Pathog. 5, e1000433 (2009).
Doria-Rose, N.A. et al. J. Virol. 83, 188–199 (2009).
Mahalanabis, M. et al. J. Virol. 83, 662–672 (2009).
Sather, D.N. et al. J. Virol. 83, 757–769 (2009).
Wrammert, J. et al. Nature 453, 667–671 (2008).
Scheid, J.F. et al. Nature 458, 636–640 (2009).
Li, Y. et al. J. Virol. 83, 1045–1059 (2009).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Haigwood, N., Hirsch, V. Blocking and tackling HIV. Nat Med 15, 841–842 (2009). https://doi.org/10.1038/nm0809-841
Issue Date:
DOI: https://doi.org/10.1038/nm0809-841
